Kenvue's Net Income Jumps Amidst Sales Dip, Announces Kimberly-Clark Merger

TL;DR

**Kenvue's net income is up, but sales are down, and the Kimberly-Clark merger is a bold move to buy growth, so watch for integration risks.**

AI Summary

Kenvue Inc. reported a net income of $398 million for the fiscal three months ended September 28, 2025, an increase from $383 million in the prior year, representing a 3.9% rise. For the nine months, net income surged to $1,140 million from $737 million, a substantial 54.7% increase. However, net sales decreased to $3,764 million for the quarter from $3,899 million, a 3.5% decline, and for the nine months, net sales fell to $11,344 million from $11,793 million, a 3.8% drop. Operating income for the nine months significantly improved to $1,879 million from $1,358 million, partly due to the absence of the $578 million impairment charges recorded in the prior year. The company announced a significant strategic development: on November 2, 2025, Kenvue entered into a Merger Agreement with Kimberly-Clark Corporation, indicating a major business combination. Restructuring expenses increased to $84 million for the quarter and $204 million for the nine months, up from $31 million and $120 million respectively, reflecting ongoing operational adjustments. Cash and cash equivalents increased to $1,139 million as of September 28, 2025, from $1,070 million at December 29, 2024. The company also noted risks related to its ability to expand globally, competitive pressures, and product reliability concerns.

Why It Matters

This filing is critical for investors as Kenvue's proposed merger with Kimberly-Clark Corporation signals a major shift in the consumer health and personal care landscape, potentially creating a formidable competitor to industry giants like Procter & Gamble and Unilever. While net income grew by 54.7% for the nine months, the persistent decline in net sales by 3.8% over the same period raises questions about organic growth and market share in a highly competitive environment. Employees of both Kenvue and Kimberly-Clark face uncertainty and potential restructuring, while customers could see changes in product portfolios and brand focus. The merger's success hinges on realizing synergies and effectively integrating diverse product lines, which will be closely watched by the broader market.

Risk Assessment

Risk Level: high — The risk level is high primarily due to the proposed merger with Kimberly-Clark Corporation, which introduces significant integration risks and uncertainties, as explicitly stated in the filing's 'Cautionary Note Regarding Forward-Looking Statements.' Additionally, the company faces ongoing challenges with declining net sales, down 3.5% for the quarter and 3.8% for the nine months, alongside increased restructuring expenses of $204 million for the nine months, indicating persistent operational adjustments and potential market pressures.

Analyst Insight

Investors should closely monitor the progress and terms of the Kenvue-Kimberly-Clark merger, as successful integration and synergy realization will be crucial for future value. Given the declining net sales, investors should scrutinize the combined entity's strategy for organic growth and market share expansion. Consider holding off on new positions until more clarity emerges on the merger's financial impact and operational execution.

Financial Highlights

debt To Equity

1.56

revenue

$11,344M

operating Margin

16.57%

total Assets

$27,248M

total Debt

$8,973M

net Income

$1,140M

eps

$0.59

gross Margin

58.67%

cash Position

$1,139M

revenue Growth

-3.8%

Revenue Breakdown

Key Numbers

• $398M — Net income for Q3 2025 (Increased from $383 million in Q3 2024, a 3.9% rise)
• $1,140M — Net income for nine months ended Sept 28, 2025 (Increased from $737 million in prior year, a 54.7% rise)
• $3,764M — Net sales for Q3 2025 (Decreased from $3,899 million in Q3 2024, a 3.5% decline)
• $11,344M — Net sales for nine months ended Sept 28, 2025 (Decreased from $11,793 million in prior year, a 3.8% decline)
• $1,879M — Operating income for nine months ended Sept 28, 2025 (Increased from $1,358 million in prior year, partly due to absence of impairment charges)
• $204M — Restructuring expenses for nine months ended Sept 28, 2025 (Increased from $120 million in prior year)
• $1,139M — Cash and cash equivalents as of Sept 28, 2025 (Increased from $1,070 million at Dec 29, 2024)
• $578M — Impairment charges in prior nine-month period (Not present in current nine-month period, contributing to higher operating income)

Key Players & Entities

• Kenvue Inc. (company) — Registrant and consumer health company
• Kimberly-Clark Corporation (company) — Merger partner for Kenvue
• Johnson & Johnson (company) — Former parent company of Kenvue
• New York Stock Exchange (regulator) — Exchange where KVUE common stock trades
• SEC (regulator) — U.S. Securities and Exchange Commission
• Self Care (company) — Kenvue business segment
• Skin Health and Beauty (company) — Kenvue business segment
• Essential Health (company) — Kenvue business segment

FAQ

Risk Factors

• Global Expansion Challenges [medium — market]: The company faces risks related to its ability to expand globally. This could impact future revenue growth and market share if Kenvue cannot effectively penetrate new international markets or adapt its products to local demands.
• Competitive Pressures [high — market]: Kenvue operates in a highly competitive landscape. Intense competition could lead to pricing pressures, reduced market share, and increased marketing expenses, impacting profitability.
• Product Reliability Concerns [high — operational]: Concerns regarding product reliability pose a significant operational risk. Issues with product quality or safety could lead to recalls, reputational damage, and potential legal liabilities, affecting sales and customer trust.

Industry Context

Kenvue operates in the consumer health sector, a market characterized by strong brand loyalty and significant competition from both established players and emerging brands. Trends include a growing consumer focus on wellness, preventative care, and personalized health solutions. The industry is also influenced by regulatory scrutiny and the need for continuous innovation to meet evolving consumer demands.

Regulatory Implications

The company operates under various regulatory frameworks governing product safety, labeling, and marketing across different geographies. Compliance with these regulations is critical to avoid penalties, product recalls, and reputational damage. Changes in regulatory requirements, particularly concerning ingredient disclosures or advertising claims, could necessitate costly adjustments to product lines and marketing strategies.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-11-02: Merger Agreement with Kimberly-Clark Corporation — Indicates a major strategic development and potential business combination, which will significantly alter the company's structure and future operations.
• 2025-09-28: End of Fiscal Third Quarter — Reporting period for the condensed consolidated financial statements, showing net sales of $3,764M and net income of $398M.
• 2025-09-28: End of Nine-Month Period — Reporting period for the condensed consolidated financial statements, showing net sales of $11,344M and net income of $1,140M.
• 2024-09-29: End of Prior Year Fiscal Third Quarter — Comparison period for Q3 2025 results, with net sales of $3,899M and net income of $383M.
• 2024-09-29: End of Prior Year Nine-Month Period — Comparison period for the nine months ended Sept 28, 2025, with net sales of $11,793M and net income of $737M.
• 2024-12-29: End of Prior Fiscal Year — Balance sheet comparison date, with cash and cash equivalents of $1,070M.

Glossary

Restructuring expenses

Costs incurred as part of a plan to reorganize a company's operations, often involving layoffs, facility closures, or business unit divestitures. (Increased to $84M for the quarter and $204M for the nine months, indicating ongoing operational adjustments and associated costs.)

Impairment charges

A reduction in the carrying value of an asset when its fair value is less than its book value, often due to a decline in economic conditions or the asset's performance. (The absence of $578M in impairment charges in the current nine-month period significantly contributed to the improvement in operating income compared to the prior year.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Represents a significant portion of Kenvue's assets ($9,441M as of Sept 28, 2025), reflecting past acquisitions.)

Accumulated other comprehensive loss

A component of equity that includes unrealized gains and losses on certain investments, foreign currency translation adjustments, and pension adjustments. (Stands at $(5,130)M as of Sept 28, 2025, indicating significant cumulative unrealized losses impacting total equity.)

Diluted Net Income Per Share

Net income per share calculated after accounting for all dilutive potential common shares, such as stock options and convertible securities. (Reported at $0.59 for the nine months ended September 28, 2025, compared to $0.38 in the prior year, showing improved per-share profitability.)

Year-Over-Year Comparison

Compared to the prior year, Kenvue Inc. reported a 3.9% increase in net income for the third quarter of 2025 ($398M vs $383M) and a substantial 54.7% increase for the nine-month period ($1,140M vs $737M). However, net sales saw a decline, down 3.5% for the quarter ($3,764M vs $3,899M) and 3.8% for the nine months ($11,344M vs $11,793M). Operating income for the nine months significantly improved due to the absence of $578 million in impairment charges from the prior year. Restructuring expenses have increased, and new risks related to global expansion, competition, and product reliability have been noted.

Key Financial Figures

• $0.01 K — ch registered Common Stock, Par Value $0.01 KVUE New York Stock Exchange Indicate b
• $0.01 — , 1,915,802,170 shares of Common Stock, $0.01 par value, were outstanding. TABLE OF

Filing Documents

• kvue-20250928.htm (10-Q) — 2125KB
• exhibit102-perryrsuawardag.htm (EX-10.2) — 101KB
• exhibit103-perryoptionawar.htm (EX-10.3) — 123KB
• a20253qex311ceocertificati.htm (EX-31.1) — 10KB
• a20253qex312cfocertificati.htm (EX-31.2) — 10KB
• a20253qex321ceocertificati.htm (EX-32.1) — 6KB
• a20253qex322cfocertificati.htm (EX-32.2) — 5KB
• 0001944048-25-000198.txt ( ) — 10767KB
• kvue-20250928.xsd (EX-101.SCH) — 56KB
• kvue-20250928_cal.xml (EX-101.CAL) — 79KB
• kvue-20250928_def.xml (EX-101.DEF) — 280KB
• kvue-20250928_lab.xml (EX-101.LAB) — 648KB
• kvue-20250928_pre.xml (EX-101.PRE) — 504KB
• kvue-20250928_htm.xml (XML) — 2131KB

—Financial Information

Part I—Financial Information Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Income 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 40 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 59 Item 4.

Controls and Procedures

Controls and Procedures 59

—Other Information

Part II—Other Information Item 1.

Legal Proceedings

Legal Proceedings 60 Item 1A.

Risk Factors

Risk Factors 60 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 63 Item 5. Other Information 63 Item 6. Exhibits 64

Signatures

Signatures 65 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q and Kenvue Inc.'s other publicly available documents contain forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives, and projections about the future. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates," and other words of similar meaning in conjunction with, among other things: discussions of future operations expected operating results and financial performance impact of planned acquisitions and dispositions our strategy for growth and cost savings product development activities regulatory approvals market position; expenditures; the effects of the Separation (as defined in Note 1, "Description of the Company and Summary of Significant Accounting Policies—Description of the Company and Business Segments," to the Condensed Consolidated Financial Statements included herein) on our business; and our proposed Transaction (as defined in Note 16, "Subsequent Events," to the Condensed Consolidated Financial Statements included herein). As used in this Quarterly Report on Form 10-Q, "Kenvue," the "Company," "we," "us," "our," and similar terms include Kenvue Inc. and its subsidiaries, unless the context indicates otherwise. Because forward-looking statements are based on current beliefs, expectations, and assumptions regarding future events, they are subject to risks, uncertainties, and changes that are difficult to predict and many of which are outside of our control. You should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, our actual results and financial condition could vary materially fr

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements KENVUE INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited; Dollars in Millions, Except Per Share Data; Shares in Thousands) September 28, 2025 December 29, 2024 Assets Current assets Cash and cash equivalents $ 1,139 $ 1,070 Trade receivables, less allowances for credit losses ($ 25 and $ 26 as of September 28, 2025 and December 29, 2024, respectively) 2,416 2,165 Inventories 1,794 1,591 Prepaid expenses and other receivables 531 494 Other current assets 152 205 Total current assets 6,032 5,525 Property, plant, and equipment, net 2,092 1,849 Intangible assets, net 8,716 8,474 Goodwill 9,441 8,843 Deferred taxes on income 237 184 Other assets 730 726 Total Assets $ 27,248 $ 25,601 Liabilities and Stockholders' Equity Current liabilities Loans and notes payable $ 1,913 $ 1,552 Accounts payable 2,445 2,254 Accrued liabilities 958 1,132 Accrued rebates, returns, and promotions 737 727 Accrued taxes on income 103 74 Total current liabilities 6,156 5,739 Long-term debt 7,060 7,055 Deferred taxes on income 2,425 2,261 Employee-related obligations 373 342 Other liabilities 600 536 Total liabilities 16,614 15,933 Commitments and contingencies (Note 13) Stockholders' Equity Preferred stock, $ 0.01 par value, 750,000 shares authorized; no shares issued and outstanding as of September 28, 2025 and December 29, 2024 — — Common stock, $ 0.01 par value, 12,500,000 shares authorized; 1,936,118 and 1,915,731 shares issued and outstanding as of September 28, 2025, respectively; 1,924,977 and 1,913,768 shares issued and outstanding as of December 29, 2024, respectively 19 19 Additional paid-in capital 16,320 16,130 Treasury stock, 20,387 and 11,208 shares at cost as of September 28, 2025 and December 29, 2024, respectively ( 439 ) ( 242 ) Accumulated deficit ( 136 ) ( 93 ) Accumulated other comprehensive loss ( 5,130 ) ( 6,146 ) Total stockholders' equity 10,634 9,668 Total Liabilities and Stockholders' E